Moderna CEO says its cancer vaccine is not a disappointment but a blockbuster
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna’s stock tanked Thursday following a data leak for the drugmaker’s cancer-vaccine candidate, which is co-developed with Merck. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishModerna shares fell after a data leak on the cancer vaccine candidate co-developed with Merck.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna stock tanked Thursday following a data leak.
- 02The cancer-vaccine candidate is co-developed with Merck.
- 03Moderna's CEO says the product is not a disappointment.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Moderna, Inc.198.85 USDMarket closedtoday -0.62%Negative Merck & Co., Inc.140.61 USDMarket closedtoday -3.21%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets